Morfouace et al. performed high-throughput screening of a bioactive library consisting of 7,389 compounds including 830 US Food and Drug Administration-approved drugs, and they identified gemcitabine and pemetrexed as efficacious at increasing the survival of mice bearing patient-derived xenograft Group 3 medulloblastomas in which MYC is overexpressed [18]. This evidence concerns the gene MYC and medulloblastoma.